NEWS
Paul Hastings Advises Citigroup, Cantor and Stifel on Candel Therapeutics’ $100 Million Public Offering
February 20, 2026
Paul Hastings LLP advised Citigroup, Cantor and Stifel as joint bookrunning managers on Candel Therapeutics’ (Nasdaq: CADL) $100 million underwritten public offering of 18,348,624 shares of its common stock at a price of $5.45 per share. In addition, Candel has granted the underwriters a 30-day option to purchase up to 2,752,293 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about Feb. 23, 2026, subject to customary closing conditions.
Equity Capital Markets and Corporate Life Sciences chair Seo Salimi and partner Will Magioncalda led the Paul Hastings team, which included associates Elizabeth Fleming and Pranav Iyer.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.